ADRB2
ENSG00000169252
Target class
GPCR
Chromosome
5
Approved drugs
50
Clinical candidates (approved and in development)
72
- Approved drugs
- 50
- Clinical candidates (approved and in development)
- 72
- Chemical probe available
- Yes
- Target name
- ADRB2
- Gene name
- Adrenoceptor beta 2
- Gene symbol
- ADRB2
- Previous gene symbols
- ADRB2R
- Protein name
- Beta-2 adrenergic receptor (Beta-2 adrenoreceptor) (Beta-2 adrenoceptor)
- ADRBR
- BAR
- B2AR
- ARB2
- Gene biotype
- Protein coding
- Gene family
- Adrenoceptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 39
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 31.85
- Tissue specificity (Gini)
- 0.611
- Tissue specificity (tau)
- 0.849
- KEGG gene identifiers
- hsa:154
- Protein interaction confidence
- 0.833556
- Protein interaction partners
- 63
- R-HSA-390696
- R-HSA-418555
- R-HSA-5689880
- R-HSA-8856825
- R-HSA-8856828
- End position
- 148828623
- Start position
- 148826611
- Chromosome
- 5
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Golgi apparatus . Note=Colocalizes with VHL at the cell membrane (PubMed:19584355). Activated receptors are internalized into endosomes prior to their degradation in lysosomes (PubMed:20559325). Activated receptors are also detected within the Golgi apparatus (PubMed:27481942). .
- Plasma membrane
- PubMed 19584355
- PubMed 20559325
- PubMed 23166351
- PubMed 25220262
- PubMed 2831218
- PubMed 7915137
- PubMed 24056936
- PubMed 27481942
- Tissue specificity (tau)
- 0.849371
- Expression inequality (Gini)
- 0.611445
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 31.85
- Skin - Sun Exposed (Lower leg)
- 27.52
- Breast - Mammary Tissue
- 27.44
- Adipose - Subcutaneous
- 25.62
- Adipose - Visceral (Omentum)
- 19.9
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)31.85
- Skin - Sun Exposed (Lower leg)27.52
- Breast - Mammary Tissue27.44
- Adipose - Subcutaneous25.62
- Adipose - Visceral (Omentum)19.9
- Lung16.73
- Vagina12.96
- Esophagus - Mucosa9.09
- Spleen8.48
- Nerve - Tibial6.38
- Cervix - Ectocervix6.26
- Prostate6
- Esophagus - Muscularis4.96
- Esophagus - Gastroesophageal Junction4.85
- Minor Salivary Gland4.83
- Artery - Coronary4.13
- Whole Blood4.06
- Uterus3.91
- Fallopian Tube3.75
- Muscle - Skeletal3.72
- Bladder3.64
- Small Intestine - Terminal Ileum3.58
- Heart - Atrial Appendage3.47
- Liver3.41
- Cervix - Endocervix3.02
And 29 more, listed on the interactive page.
- GO:0006898
- GO:0007166
- GO:0007188
- GO:0008333
- GO:0043410
- GO:0045744
- GO:0071875
- GO:0071880
- GO:0098990
- GO:1900451
- GO:1901098
- GO:1904504
- GO:1904646
- GO:1990911
- GO:0005764
- GO:0005768
- GO:0005794
- GO:0005886
- GO:0010008
- GO:0030669
- GO:0043235
- GO:0001540
- GO:0004941
- GO:0005515
- GO:0015459
- GO:0042802
- GO:0042803
- GO:0044877
- GO:0051380
bronchospasm
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchospasm
- cardiovascular
- blood
PubMed 28216264increased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood glucose
- cardiovascular
- blood
PubMed 28216264decreased blood potassium
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood potassium
- cardiovascular
- blood
PubMed 28216264increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood pressure
- cardiovascular
- blood
PubMed 28216264Promotion, mesovarian leiomyomas
Effects
- Activation/Increase/Upregulation
Studies
- cell-based
Evidence sourcecardiovascular performance
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: cardiovascular performance
Biological samples
- cardiovascular system
Evidence sourcebradycardia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- clinical: bradycardia
Biological samples
- cardiovascular system
Evidence sourcecardiac contractility
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: cardiac contractility
Biological samples
- cardiovascular system
Evidence sourcevasodilatation of the vascular beds of skeletal muscle
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: vasodilatation of the vascular beds of skeletal muscle
Biological samples
- cardiovascular system
Evidence sourcehypotonia
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypotonia
Biological samples
- cardiovascular system
Evidence sourcesmooth muscle relaxation
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: smooth muscle relaxation
Biological samples
- cardiovascular system
Evidence sourceheart failure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: heart failure
- cardiovascular
- blood
PubMed 28216264increased cardiac contractility
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased cardiac contractility
- cardiovascular
- blood
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- cardiovascular
- blood
PubMed 28216264increased QTc interval
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased QTc interval
- cardiovascular
- blood
PubMed 28216264
bronchodilation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: bronchodilation
- cardiovascular system
- pulmonary
PubMed 23197038increased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased heart rate
- cardiovascular system
- pulmonary
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hAdrb2, is one of one assay component(s) measured or calculated from the NVS_GPCR_hAdrb2 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceperipheral vasodilation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: peripheral vasodilation
- cardiovascular system
- pulmonary
PubMed 23197038increased glycogenolysis and glucagon release
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased glycogenolysis and glucagon release
- cardiovascular system
- pulmonary
PubMed 23197038skeletal muscle tremor
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: skeletal muscle tremor
- cardiovascular system
- pulmonary
PubMed 23197038decreased blood pressure
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- pulmonary
PubMed 23197038
Related records
Trials (3,125)
- : Vascular Function in Health and Disease
- ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- "The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"
- "The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
- "The Evaluation of Stimulant Withdrawal"
- (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
- 10 Vs.15 mcg Norepinephrine Bolus in Severe Maternal Hypotension During Cesarean Delivery
- 12 / 48 Week Pivotal PFT vs PBO in COPD I
- 12 / 48 wk Pivotal PFT vs PBO in COPD II
- 12-week Efficacy of Indacaterol
- 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- ¹³C-Methacetin Breath Test (MBT) Methodology Study
- 24 Hour Ambulatory Cardiac Oxygen Consumption
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
- 24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
Drugs (108)
- Abediterol Beta-2 adrenergic receptor agonist
- Albuterol Beta-2 adrenergic receptor agonist
- Albuterol sulfate Beta-2 adrenergic receptor agonist
- Arformoterol Beta-2 adrenergic receptor agonist
- Arformoterol tartrate Beta-2 adrenergic receptor agonist
- AZD3199 Beta-2 adrenergic receptor agonist
- Bambuterol Beta-2 adrenergic receptor agonist
- Bamosiran Beta-2 adrenergic receptor mRNA RNAi inhibitor
- Batefenterol Beta-2 adrenergic receptor agonist
- Bedoradrine Beta-2 adrenergic receptor agonist
- Bedoradrine sulfate Beta-2 adrenergic receptor agonist
- Bitolterol Beta-2 adrenergic receptor agonist
- Bitolterol mesylate Beta-2 adrenergic receptor agonist
- Bucindolol Beta-2 adrenergic receptor antagonist
- Bucindolol hydrochloride Beta-2 adrenergic receptor antagonist
- Carmoterol Beta-2 adrenergic receptor agonist
- Carteolol Adrenergic receptor beta antagonist
- Carteolol hydrochloride Adrenergic receptor beta antagonist
- Carvedilol Adrenergic receptor beta antagonist
- Carvedilol phosphate Adrenergic receptor beta antagonist